Supporting Advanced Dementia in people with Down syndrome and other intellectual disabilities: Consensus Statement of the International Summit on Intellectual Disability and Dementia by McCarron, Mary et al.
1 
JIDR 
Supporting Advanced Dementia in people with Down syndrome and other intellectual disabilities: 
Consensus Statement of the International Summit on Intellectual Disability and Dementia  
Mary McCarron1, Philip McCallion2, Karen Watchman3, Matthew P. Janicki4, Antonia Coppus5, Kathy 
Service6, Juan Fortea7, Mary Hogan8, Evelyn Reilly9, Sandy Stemp10 
Abstract 
The International Summit on Intellectual Disability and Dementia (Glasgow, Scotland; October 
2016) noted that advanced dementia can be categorised as that stage of dementia progression 
characterised by significant losses in cognitive and physical function, including a high 
probability of further deterioration and leading to death.  The questions before the Summit were 
whether there were similarities and differences in expressions of advanced dementia between 
adults with intellectual disability and adults in the general population.   
The Summit noted challenges in the staging of advanced dementia in people with ID with the 
criteria in measures designed to stage dementia in the general population heavily weighted on 
notable impairment in activities of daily living. For many people with an intellectual disability 
(ID) there is already dependence in these domains generally related to the individuals pre-
existing level of intellectual impairment, i.e., totally unrelated to dementia. Hence, the summit 
agreed that as was true in achieving diagnosis, it is also imperative in determining advanced 
dementia that change is measured from the person’s prior functioning in combination with 
clinical impressions of continuing and marked decline and of increasing co-morbidity, including 
particular attention to late onset epilepsy in people with Down syndrome.  It was further noted 
that quality care planning must recognise the greater likelihood of physical symptoms, 
comorbidities, immobility and neuropathological deterioration.   
The Summit recommended an investment in research to more clearly identify measures of 
person-specific additional decline for ascertaining advanced dementia, inform practice guidelines 
to aid clinicians and service providers, and to identify specific markers that signal such 
additional decline and progression into advanced dementia among people with various levels of 
pre-existing intellectual impairment. 
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Introduction 
As part of an invitational meeting (the International Summit on Intellectual Disability and 
Dementia held in Glasgow, Scotland, on October 13-14, 2016) attendees examined various 
dementia-related issues affecting people with intellectual disability and particularly those 
presenting with advanced dementia.  Given that criteria defined dementia is at times 2-5 times 
more common among some persons with an intellectual disability, with a shift in risk to younger 
age groups compared to the general population (Strydom, Hassiotis, King, & Livingston, 2009), 
this topic was given special consideration. 
 Specifically, there was consideration of the characteristics of advanced dementia in 
adults with intellectual disability and of the similarities and differences in expressions of 
advanced dementia in adults in the general population and what differences were notable 
between adults subject to early-onset dementia (such as those with Down syndrome) and other 
aetiologies of intellectual disability.  One challenge was to define what might be considered 
advanced dementia in adults with Down syndrome or other intellectual disability and to examine 
the utility and/or usefulness of tools developed to identify stages of dementia in the general 
population.  These considerations added to the Summit’s outcomes, which resulted in a series of 
consensus statements and reports, including this statement on advanced dementia.   
Background  
Adults with intellectual disability are as susceptible to Alzheimer’s disease (AD) and other 
causes of dementia generally at the same rates as persons in the general population; however, 
adults with Down syndrome are at greater risk (Strydom et al., 2010), with many such adults 
showing symptoms of early onset in their late 40s or early 50s (Coppus et al.,, 2006; Holland, 
Hon, Huppert & Stevens, 2000; McCarron, McCallion, Reilly, & Mulryan, 2014).   People with 
ID who do not have a diagnosis of Down syndrome or people with ID from other aetiologies 
generally show onset symptoms at an age mirroring the general population.  It is well established 
that diagnosing dementia in people with intellectual disability is more complex than in the 
general population due to varying levels of pre-existing intellectual impairment, communication 
difficulties, and frequent staff turn-over with a loss of informants with knowledge of the 
individual’s level of functioning, particularly in basic and instrumental activities of daily living.  
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One additional factor complicating identifying advanced dementia in people with Down 
syndrome and other intellectual disability is the variations in innate cognitive functions, and 
confusion over whether these deficits are a reflection of intellectual disability or of the 
progression of dementia. 
Advanced dementia:  Dementia in an advanced stage is usually characterised as when 
progression proceeds to where significant losses in function are evident and where there is a high 
probability of further deterioration, leading to death (Alzheimer’s Australia, n.d.; Alzheimer’s 
Society, 2017). In most staging schemes, this latter stage generally signals extensive personal 
care by carers and can last up to 2.5 years (Reisberg, Ferris, deLeon, & Crook, 1982; DeLeon & 
Reisberg, 1999).  In the general population, the clinical features of advanced stage dementia have 
been previously described as: ‘profound memory deficits (e.g., inability to recognise family), 
minimal verbal communication, loss of ambulatory abilities, the inability to perform activities of 
daily living, and urinary and faecal incontinence. The most common clinical complications are 
eating problems and infections, and these require management decisions” (p. 2534; Mitchell, 
2015).  The clinical features of advanced dementia in people with Down syndrome and other 
intellectual disability, (as noted in Table 1) are similar to those described by Mitchell (2015). 
One important exception is that among adults with Down syndrome, rates of late onset seizures 
may range up to 70-80% (Crespel, Gonzalez, Coubes, & Gelisse, 2007; Menendez, 2005; 
McCarron et al., 2014). 
 
Determination of advanced dementia:  The identification of the presence of dementia 
can be confounded by lack of knowledge among many health and social care professionals on 
the clinical presentation of dementia in people with intellectual disability and the applicability of 
commonly used standardised test instruments.  At the most basic level of screening and 
establishing symptoms of dementia, instruments used in the general population, such as the 
Mini-Mental State Examination (MMSE) (Folstein, Folstein, & McHugh, 1975), and assessment 
scales such as  the Clinical Dementia Rating Scale (Morris, 1993) and the Alzheimer’s Disease 
Assessment Scale – Cognitive section (ADAS-Cog; Rosen et al., 2004) are inappropriate for 
people with pre-existing cognitive impairment, as most people with even mild intellectual 
disability are likely to meet screening cut off criteria for these instruments.  Thus, most clinicians 
tend to turn to specialised instruments applicable to persons with Down syndrome and other 
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intellectual disability. A number of sources have identified the utility of a number of these 
specialty instruments (see Alyward, Burt, Thorpe, Lai, & Dalton, 1997; British Psychological 
Society, 2015; Jokenin et al., 2013). 
 
Increasingly, it is recognised that diagnosing dementia in people with Down syndrome 
and other intellectual disability is predicated on having an understanding of decline /change from 
the individual’s previous level of functioning (see for example Strydom & Hassiotis, 2003). To 
increase diagnostic accuracy, it is important to have a reliable baseline measure of functioning 
and a key informant who has known the individual over an extended period of time.  
Unfortunately, baseline measurement of functioning is more often an exception rather than the 
norm, with frequent staff changes in out-of-home placements and lack of regular assessment in 
family situations often meaning that there is poor knowledge, understanding, or measurement of 
decline/change. This often results in the individual progressing to a more advanced stage of 
dementia before any diagnosis is made, further confounding difficulties in the staging of 
dementia.  Moreover, dementia may present differentially within various syndromes or 
aetiologies of intellectual disability. For all of these reasons, the ability to ascertain advanced 
dementia will be improved if there is earlier and more comprehensive attention to the 
development of baseline functioning and the pursuit of earlier diagnosis so that there is a new 
time of diagnosis baseline established against which progression to advanced dementia can be 
measured and ascertained. The same measures now being more widely used and recommended 
in the diagnosis of dementia in people with Down syndrome and other intellectual disabilities are 
likely to be the most sensitive to measuring such changes. However, clinical impressions and 
information form informants will also be important.           
Standard neuroimaging such as CT/MRI scanning generally used to support diagnosis in 
the general population is less helpful in people with intellectual disability. The most consistent 
structural change of early Alzheimer’s dementia in the general population is atrophy of the 
medial temporal lobe, but among people with Down syndrome, for example, medial temporal 
lobe atrophy occurs at an earlier age and is totally unrelated to dementia. Due to lack of 
standardisation in other syndromes, neuroimaging is of limited value to the diagnosis of 
dementia in people with intellectual disability (British Psychological Society, 2015). All of these 
issues add additional complexity in diagnosing and staging of dementia in people with 
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intellectual disability and make it difficult to recognise the transition across stages, including 
when the person has progressed to a more advanced stage.  
There is even greater diagnostic uncertainty in older age as many adults with intellectual 
disability, especially those with Down syndrome, are also at increased risk of other health 
conditions which often mimic dementia and/or confound diagnosis such as hypothyroidism, 
sensory impairments, B12 and folate deficiency, and depression (Prasher, 2005).  The presence 
of these conditions may further complicate staging diagnosis.  As well as increased risk of earlier 
age of onset, syndromes associated with precocious ageing (e.g., Cockayne, Sanfillipo, and 
Williams syndromes) may mean a precipitous decline and shorter dementia duration (Janicki, 
Henderson, Rubin, & the Neurodevelopmental Conditions Study Group, 2008), although the 
literature on the prevalence of dementia in these ‘orphan’ syndromes is sparse. Precipitous 
decline and shorter duration of dementia adds to the difficulty in staging. There are similar 
challenges with persons with intellectual disability who also have been diagnosed with head 
trauma or brain injury (Nagdee, 2010).   
 
 The Summit, after a review of related anecdotal and clinical information, as well as 
research data, supports characterising late or advanced stage dementia into its neurocognitive, 
functional, nutritional, and comorbid health condition aspects. Data from a number of studies, 
including an Irish cohort of 77 women with Down syndrome followed over 20 years from pre-
diagnosis to diagnosis to end stage disease (McCarron et al 2014; McCarron et al., under review) 
and from other studies, for example Coppus and colleagues (2008), have confirmed the value of 
this approach to establishing advanced dementia.   
 
The Summit noted increased interest in staging in light of the progressive nature of 
dementia and the need to tailor care, environments, work and day programming to changing 
needs (Jokinen et al., 2013; McCarron, Gill, Lawlor, & Begley, 2002: McCarron & Griffiths, 
2003; NTG, 2012). However, staging in the general population is based upon measurement of 
notable impairment of daily activities. For many people with intellectual disability there is 
dependence in basic ADLs (activities of daily living) mostly due to the pre-existing intellectual 
disability and therefore decisions to change care due to advanced dementia must be informed by 
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a more robust assessment of decline into advanced dementia. As is true for any assessment for 
people with Down syndrome and other intellectual disability, it is important to focus on changes 
from the person’s prior functioning and/or in new symptoms as compared to prior health status. 
For advanced dementia these changes are from the functioning and the staging established at 
time of diagnosis. Again, decline and staging of dementia in this population appears best 
achieved by annual assessments (from the age of 40 in Down syndrome and from the age of 50 
in people with other ID) using scales recommended for persons with Down syndrome and other 
intellectual disabilities (Alyward et al., 1997; Zellinger et al., 2013). 
 
The Summit participants agreed that reliance upon information from informants as well 
as objective measures is always an issue in dementia diagnosis (Cordell et al., 2013), but is 
particularly of concern for people with DS and other intellectual disabilities who frequently have 
communication difficulties.  The sensitivity of assessment instruments seeking information on 
changes to baseline functioning are also challenged by the subtleness of change (Mulryan et al, 
2009). There is a growing history on the use of such instruments in people with Down syndrome 
and to some extent with other intellectual disabilities and insights have emerged on the strengths 
and weaknesses of available measures (for a review see Strydom & Hassiotis, 2003;  Jokinen et 
al., 2013; Zellinger, et al., 2013). There is a need for a similar attention to instrumentation for the 
identifying progression into the later stages of dementia.   One attempt to operationalise 
identifying possible progression to an end-of-life state in advanced dementia can be found in 
McCallion et al., (2017).  
 
Ascertaining Advanced Dementia 
 
For the general population, there are recommended instruments for ascertaining the 
transition to advanced dementia (Sheehan, 2012), such as the Global Deterioration Scale (GDS; 
Reisberg et al., 1982) and the Functional Assessment Staging Tool (FAST; see stage 7; Reisberg, 
1988).  These instruments combine clinical impressions with data on growing inability of the 
person to dress, prepare meals, eat and drink independently, walk without assistance, attend to 
personal hygiene, maintain continence of urine and stool, and speak or meaningfully 
communicate.   Clinical impressions are also called for in assessing people with Down syndrome 
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and other intellectual disabilities but activities of daily living items have little utility in assessing 
advanced dementia in people with Down syndrome and other intellectual disabilities, as many 
already have such challenges and deficits unrelated to dementia, and instead characteristic of 
their pre-existing level of intellectual impairment. 
The combination of existing life-long cognitive impairments among people with 
intellectual disability, along with compromises due to dementia, frequently mean that what 
would otherwise be considered relatively small changes in functioning in the general population 
could become major changes for a person with with Down syndrome and other intellectual 
disabilities, depending on their level of functioning.  
 Therefore, all of these factors have implications for the staging of dementia in people 
with Down syndrome and other intellectual disabilities using instruments such as the Global 
Deterioration Scale (GDS) and the Functional Assessment Staging Test (FAST) validated for use 
in the general population.  The pre-existing difficulties apparent in many people with with Down 
syndrome and other intellectual disabilities in relation to communication, mobility, and ADLs 
may mean these instruments may prematurely categorise those adults with intellectual disability 
as being at an advanced stage of dementia. By way of illustration, data from one major study 
(McCarron et al., 2011), showed that 92.2% of adults with severe/profound intellectual disability 
with no dementia diagnosis had difficulty in making themselves understood when speaking, 78% 
required assistance with eating, and 80% required assistance with dressing, items that would 
cause them to be scored with advanced dementia in dementia staging scales (they would score as 
stage 6 of the FAST tool) used in the general population. The use of standard ADL/IADL 
instruments if compared to the person’s own prior level of functioning as opposed to scale norms 
may still be useful in assessing people with with Down syndrome and other intellectual 
disabilities, even if the resulting rates of change are small (Strydom & Hassiotis, 2003). 
 
 The Summit believes that it may be premature to determine if the existing general 
population instruments are of value or if new instruments or criteria need to be established for 
people with Down syndrome and other intellectual disabilities. Instead, it may be of more value 
to develop better understandings of the presentation of stages of dementia, particularly advanced 
dementia, in people with with Down syndrome and other intellectual disabilities, in order to 
inform decisions about the best measures to be used.  The literature is more developed for those 
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with Down syndrome and some unique issues for this group such as early onset and a clearer 
relationship with epilepsy are already emerging. Nevertheless, the Summit participants also 
believed that more research is needed in defining behaviour and function in adults with 
intellectual disability in the later stages of dementia, and determining whether differences in 
expression do in fact exist among syndromes and whether, as a group, adults with Down 
syndrome differ significantly in latter stage expression from other adults with intellectual 
disability from other aetiologies. 
 The Summit further supports that any  use of general population instruments for staging 
dementia be informed by (1) a comparison with the person’s prior level of functioning at time of 
diagnosis, (2) a recognition that small changes in functioning are significant changes for people 
with intellectual disability, and that (3) there is a need to utilise key informant information to 
monitor for symptoms of ill-health that may be signs of increased co-morbidity and frailty that 
co-exist with advanced dementia, (4) it is important to maintain particular vigilance to identify 
such subtle changes, and (5) among adults with Down syndrome, special attention should be paid 
to the development of new late-onset seizures. 
 
Developing Responsive Quality Services  
The Summit agrees that in advanced dementia the changes in functioning and the needs for 
support often call for a shift in the focus of care management, to increased attention to personal 
care and resourcing of skilled nursing and medical support.  Care planning and resourcing must 
recognise the greater likelihood of: 
• pain, chronic constipation, sensory impairments, oral and pharyngeal dysphasia with 
major challenges with eating, drinking and difficulties with swallowing.  
• recurrent chest and urinary tract infections, initially difficult to recognise and which, 
leading to treatable acute and re-occurring episodes of delirium, may instead be 
misinterpreted as dementia advancing.  
• skin integrity and complications of immobility concerns.  
• management needs for seizures and other co-morbid health conditions such as 
hypothyroidism, arthritis and diabetes (McCarron et al 2017; Prasher, 2005, McCarron et 
al., 2002).  
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Consequently, the Summit contends that, more practically, particularly in advanced dementia, 
addressing the physical, emotional, psychological and spiritual care needs of the person is 
imperative. The dramatic and extensive changes in care needed further emphasise the need for 
more accurate establishment of when persons with Down syndrome and other intellectual 
disability are moving toward the advanced dementia stage. A systematic approach is also needed 
to support such assessments and the Summit acknowledges anecdotal support for using what has 
been called the AFIRM framework (see Figure 1) (Irish Hospice Foundation, 2015).  
 
Insert Figure 1 About Here 
 
The Summit agreed with and supports various consensus reports (e.g., WHO 2002, 2016; 
McCarron, 2009; Mitchell et al., 2009) that guided by understandings of futile and comfort care, 
and person-centred, relationship-centred and palliative principles, care strategies that support 
effective and compassionate decision-making for persons with intellectual disability and 
advanced dementia should include: 
- Determining what is in the ‘best interest’ of the person in light of the terminal nature of 
dementia.  
- Establishing the intent of treatment and the potential for beneficial outcomes vs. burden.  
- Recognising that care decisions are best determined by care teams when they reflect the 
person’s wishes, and family/friend input. 
- Pursuing care management using a five-step process: 1) clarify the clinical situation, 2) 
establish primary goals of care, 3) present the treatment options and their risks and 
benefits, 4) weigh the options against values and preferences, and 5) provide additional 
and on-going support. 
 
Commentary 
 The Summit noted concerns related to identifying transition to an advanced stage of 
dementia for persons with Down syndrome and other intellectual disabilities.  The Summit 
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concluded that the advanced dementia stage is also an emotional and value laden time 
complicated by relationship bonds (staff as well as family) and conflicts, and limited ability to 
know and understand the wishes of the person. Understanding that the person has arrived at or is 
approaching the advanced stage of dementia is important in determining and modifying 
recommended approaches to care.  Having discussions about advanced dementia care is not a 
simple undertaking and it requires all staff/family supporting the person to be able to 
acknowledge and understand the person’s level of understanding, their life history, their ability 
and involvement in life decisions prior to dementia and to agree on the stage of dementia arrived 
at (see McCallion et al., 2017).  
 
Advanced dementia may signal the last stage of neurodegeneration associated with 
dementia, but for adults with Down syndrome as well for those with other intellectual disabilities 
there remains imprecision in measurement.  Further, as measurement improves there must also 
be the capacity to offer responsive care practices which aim to improve the quality of life and 
death for the person through the prevention and relief of suffering by means of early 
identification and impeccable assessment and treatment of pain and other problems, physical, 
psychosocial and spiritual (WHO, 2016).  Such considerations also led the Summit participants 
to make the following recommendations: 
1. Continue attention to systematic baseline screening, assessment and follow up of people 
with Down syndrome and other intellectual disabilities using agreed standardised 
instruments  
2. Compare the trajectory of dementia in people with Down syndrome to trajectories in 
people with intellectual disability from other aetiologies      
3. Undertake research to develop more valid and reliable instruments for assessing 
advanced dementia-related cognitive and physical deterioration among adults with Down 
syndrome and people with intellectual disability. 
4. Develop practice guidelines and widespread related training and education to support 
quality care when adults with an intellectual disability have advanced dementia. 
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5.  Identify additional markers and prognostication models that may help signal decline and 
progression into advanced dementia among people with various levels of pre-existing 
intellectual impairment  
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Figure 1: Characteristics of Advanced Dementia for Persons with Down Syndrome and other 
Intellectual Disabilities  
Neurocognitive Progressive worsening memory 
Inability to verbally communicate 
Apathy - depression 
Confusion and disorientation (place, time, person) 
Delirium 
Unresponsiveness 
Functional Immobility with hypertonia 
Need for total assistance of ADLs 
Incontinence 
Frailty 
Weakness, fatigue 
Nutritional Loss of appetite 
Lack of ability to self-feed 
Swallowing difficulties 
Propensity to aspirate 
Co-morbid health conditions Seizures in Down syndrome 
Constipation and complications of immobility 
Respiratory difficulties and repeat pneumonia 
 
Sources: McCarron et al 2014; Coppus et al., 2008; Cosgrave, 2000; McCarron et al., 2005, Prasher, 
2005; Strydom et al., 2010; Visser, 1997.  
 
 
